Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 7 | EJNMMI Radiopharmacy and Chemistry

Fig. 7

From: Auger electrons for cancer therapy – a review

Fig. 7

111In-NLS-trastuzumab is an example of a targeted Auger electron (AE)-emitting radioimmunotherapeutic (RIT) agent composed of the anti-HER2 monoclonal antibody, trastuzumab modified with nuclear translocation sequence (NLS in red) peptides and benzylisothiocyanate DTPA (BzDTPA) to complex 111In. 111In-NLS-trastuzumab is internalised by HER2-overexpressing breast cancer cells and is transported to the cell nucleus, where the AEs cause lethal DNA double-strand breaks (DSBs) (Costantini et al. 2007)

Back to article page